- Home
- BHF vs CELC Comparison
BHF vs CELC Comparison
Compare BHF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHF | CELC |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BHF | CELC |
|---|---|---|
| Price | $59.50 | $109.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $58.14 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 821.4K | 537.3K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.09 | N/A |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | $4.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.16 | $7.58 |
| 52 Week High | $66.33 | $120.32 |
Technical Indicators
Market Signals| Indicator | BHF | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 48.65 |
| Support Level | $59.01 | $97.75 |
| Resistance Level | $60.77 | $117.27 |
| Average True Range (ATR) | 0.85 | 5.28 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 22.37 | 41.93 |
Price Performance
Historical ComparisonAbout BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.